Seres Therapeutics Inc
Seres Therapeutics (MCRB) is a small-cap biotechnology company developing microbiome-based therapeutics that aim to modulate the gut ecosystem to treat gastrointestinal and systemic conditions. Investors should know the firm is research- and pipeline-driven, with value tied to clinical trial progress, partnerships and regulatory milestones rather than steady revenues. As with many biotech companies of this size (market cap ≈ $164M), the share price can be highly volatile and subject to binary outcomes from clinical data and regulatory decisions. The business may pursue collaborations or licensing to fund development and scale commercialisation. For investors assessing Seres, focus on trial design, cash runway, partnership agreements and regulatory feedback. This information is educational only — not personal financial advice. Biotech investing carries significant risk: values can rise and fall and past performance is not a guide to future returns. Consider your risk tolerance and seek professional advice if needed before making investment decisions.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Seres Therapeutics stock with a target price of $4.06, indicating potential growth.
Financial Health
Seres Therapeutics shows strong financial performance with solid cash flow and book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring MCRB
MASH Drug Developers Could Attract M&A in 2025
Roche's $3.5 billion deal to acquire 89bio for its late-stage liver disease drug highlights the immense commercial potential seen in the MASH treatment landscape. This move could trigger a wave of investment and further acquisitions, benefiting other biotech firms with promising therapies for metabolic disorders.
Published: September 19, 2025
Explore BasketMASH Biotech Stocks: What's Next After Roche Deal
Roche's acquisition of 89bio for its late-stage liver disease drug highlights a major strategic investment in the MASH treatment space. This move could increase the valuation of other biotech companies developing therapies for metabolic disorders as they become attractive M&A targets.
Published: September 18, 2025
Explore BasketMicrobiome Modulators
Discover a carefully selected group of innovative biotechnology companies leveraging the untapped power of the body's microbiome. These pioneering firms are creating revolutionary therapies that target the root causes of disease by rebalancing our internal microbial ecosystems.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Milestones Ahead
Pipeline news and trial readouts can move the stock substantially, though outcomes are uncertain and may not lead to commercial success.
Microbiome Opportunity
Interest in microbiome therapeutics is growing as a new modality for GI and systemic conditions, but scientific and regulatory hurdles remain.
High Risk, High Uncertainty
Small market cap and limited revenues mean financing needs and binary outcomes are likely; consider suitability and seek professional advice where needed.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
